A new company, Wamberg Genomic Advisors, launched last week, hoping to provide a conduit to genomic testing through the insurance and employee benefit marketplaces.
Startups offering blockchain technology to support genomics and precision medicine still need to prove themselves and find markets.
The startup aims to tap into the $60 billion probiotics industry by sequencing the microbiomes of athletes to identify bacteria that improve performance.
According to one of the researchers, the model could help streamline and improve mass spec workflows aimed at measuring proteins in extremely small samples.
Tempus will work with the center to develop personalized medicine regimens for cancer patients, initially focusing on hematological and pancreatic malignancies.
Genome and transcriptome sequences from hundreds of pediatric cancer cases led to somatic mutations and fusions suspected of producing potentially targetable antigens.
The investment bank began coverage with an Outperform rating, noting that Horizon's recent acquisition of Dharmacon is highly complementary and synergistic.
The molecular diagnostics firm was told on Wednesday that it is again in compliance with a rule calling for a $1 minimum bid on its share price.
The team aims to release the new resource sometime next year, with the hope that it will become as widely used as other institute databases.
The company plans to launch a test for gram-negative bacteria next, and will work with developers and freelancers to develop additional assay content
The researchers used this approach to show how non-coding variation associated with human immune dysfunction alters context-specific gene programs.
GenePattern Notebook, online since April, is meant to aggregate text, graphics, and computer code for analysis against the GenePattern bioinformatics database.
Reporting on aneuploidies across all chromosomes could improve the accuracy of some NIPTs and provide information about miscarriage risk and other complications.
Investigators used gene expression and immunological profiling to detect distinct immune responses in dengue virus-infected children with or without symptoms.
The company also said that net income for the first half of 2017 rose 18 percent year over year to €101 million from €85.7 million.
The study will perform next-generation sequencing on archival tumor tissue from 200 individuals with metastatic urothelial cancer.